0001104659-22-033392.txt : 20220314 0001104659-22-033392.hdr.sgml : 20220314 20220314170315 ACCESSION NUMBER: 0001104659-22-033392 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220310 FILED AS OF DATE: 20220314 DATE AS OF CHANGE: 20220314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Korbel Gregory Alan CENTRAL INDEX KEY: 0001789032 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39069 FILM NUMBER: 22737418 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aprea Therapeutics, Inc. CENTRAL INDEX KEY: 0001781983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6095104718 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 4 1 tm229119-4_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-03-10 0 0001781983 Aprea Therapeutics, Inc. APRE 0001789032 Korbel Gregory Alan 535 BOYLSTON STREET BOSTON MA 02116 1 1 0 0 SVP, Chief Business Officer Common Stock 2022-03-10 4 A 0 16000 0 A 31841 D Common Stock 2022-03-10 4 F 0 1989 1.82 D 29852 D Stock Option (right to Buy) 1.82 2022-03-10 4 A 0 72600 0 A 2032-03-10 Common Stock 72600 72600 D These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 5,333 shares on March 10, 2023, (ii) 5,333 shares on March 10, 2024 and (iii) 5,334 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 5,000 restricted stock units Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. /s/ Scott M. Coiante, attorney-in-fact 2022-03-14